novel antineoplastic drug, oxaliplatin (Eloxatin TM , Sanofi -Synthelabo Inc., New York, NY), was approved as a second-line treatment for metastatic colon cancer in 2002 by the U.S. Food and Drug Administration and as a fi rst-line treatment in 2004. Also in 2004, Eloxatin was approved as an adjuvant therapy when used in combination with 5-fl uorouracil (5-FU) and leucovorin (LV) in patients with stage III colon cancer. This cell-cycle nonspecifi c platinum analog is being used with increasing frequency in a variety of drug regimens as a fi rstline agent in metastatic colorectal cancer (CRC), as salvage chemotherapy after the failure of standard chemotherapy agents, and in node-positive colon cancer. Patients are treated over a longer period of time to improve progression-free survival rates and quality of life. Current research involving oxaliplatin is examining its effectiveness in treating other malignancies, as well as extending the data beyond the three-year disease-free interval in the adjuvant setting (Andre et al., 2004) . A higher likelihood of hypersensitivity reactions (HSRs) exists with oxaliplatin because of its expanded indications and additional and prolonged treatment cycles. The purpose of this article is to help nurses become more familiar with oxaliplatin and improve recognition of HSRs, including the severity and scope of symptoms.
Colorectal Cancer and Treatment
CRC is the third most common cancer in men and women, accounting for 11% of all newly diagnosed cancers and 57,100 deaths annually in the United States (American Cancer Society [ACS], 2005) . ACS estimates that in 2005 about 145,290 people will be diagnosed with CRC and 56,290 will die as a result of the disease. Only 37% of CRC cases are discovered in the early stage, when the disease is asymptomatic; most patients are diagnosed at later stages and present with symptoms of rectal bleeding, abdominal pain, and/or changes in bowel habits. The primary risk factor for CRC is age, with more than 90% of cases diagnosed in individuals older than age 50 (ACS). Other risk factors include a family history of CRC, polyps, familial syndromes (i.e., hereditary polyposis), or infl ammatory bowel disease. Early-detection recommendations by ACS include annual fecal occult blood testing or sigmoidoscopy every fi ve years after age 50. Some provider groups disagree regarding which screening tests are appropriate (Mahon, 2004) . Although the debate has not altered CRC incidence rates since 1995, an approximately 1.7% decline in the mortality rate for men and women has occurred (ACS). When CRC is detected at an early, localized stage, the fi ve-year relative survival rate is 90%. This rate drops to 67% after the cancer has spread to adjacent organs or lymph nodes and 10% when distant metastases develop (ACS). Because of the decreased survival rate for patients with metastatic CRC, researchers have concentrated on fi nding new, effective agents to fi ght the disease.
Treatment for CRC may include surgery, radiation, and chemotherapy. The primary treatment is surgery for removal of the tumor and acquisition of samples of adjacent tissue and lymph nodes. Pathologic classifi cation with the tumor, node, metastasis (TNM) staging system is important as a tool to direct physicians in further management and as a prognostic indicator. The Dukes' system was used in the past, but the American Joint Committee on Cancer (2002) has recommended the TNM system because it provides greater detail and precision in the identifi cation of prognostic subgroups. This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
